COMPASS Pathways Stock
COMPASS Pathways plc
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- CEO
- Kabir Kumar Nath
- Employees
- 156
- Market cap
- $1.5 B
- IPO
- 18/09/2020
COMPASS Pathways plc is a healthcare company operating within the biotechnology industry. Headquartered in London, United Kingdom, the firm is listed on the NASDAQ and held its initial public offering on September 18, 2020. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
COMPASS Pathways stock: price history
1D
-7.5%
1W
-10.4%
1M
-22.1%
6M
+61.4%
YTD
+55.8%
1Y
+67.7%
2Y
+71.2%
5Y
-66.6%
10Y
–
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~26% stronger price swings than usual
Ask the agents about COMPASS Pathways
Analyst assessment of COMPASS Pathways
PRICE TARGET LOW
US$13.00
CONSENSUS
US$18.63
MEDIAN
US$18.00
PRICE TARGET HIGH
US$25.00
0
STRONG BUY
15
BUY
0
HOLD
0
SELL
0
STRONG SELL
15
TOTAL · Buy
As of: 07/08/2026
COMPASS Pathways stock metrics
P/E
-1.93
P/B
11.91
EV/EBITDA
-2.83
RETURN ON EQUITY
-300.2%
NET MARGIN
0.0%
DEBT/EQUITY
0.65
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
98.4%
FLOAT SHARES
136,241,668
AVG. DAILY VOLUME (30D)
2,940,597
Insider transactions (SEC)
Nath Kabir
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -7.5%
Forums (Reddit)
See the full forum history with Pro.
Institutional holders
Comparable stocks
Frequently asked questions about COMPASS Pathways stock
What does COMPASS Pathways do?
COMPASS Pathways plc is a company in the Healthcare sector, Biotechnology industry, headquartered in United Kingdom.
The CEO is Kabir Kumar Nath, the company employs around 156 people.
The IPO was on 18/09/2020; the stock trades on NASDAQ under the ticker CMPS.
What do analysts say about COMPASS Pathways stock?
15 analysts rate the stock, the consensus is Buy (as of 07/08/2026).
The average price target is US$18.63, ranging from US$13.00 to US$25.00, with a median of US$18.00.
This is an external assessment, not a statement by Market Jury.
When does COMPASS Pathways report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly 26% stronger than usual.
Does COMPASS Pathways pay a dividend?
No, COMPASS Pathways currently does not pay a dividend.
Which stocks are comparable to COMPASS Pathways?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get COMPASS Pathways stock analyzed?
Clicking "Analyze stock" lets five strategies assess COMPASS Pathways against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.